Citius Oncology's Latest Financial Move
Citius Oncology, Inc. is making significant strides in the oncology space with its recent announcement regarding a financing initiative worth approximately $9 million. The company, which specializes in pioneering cancer treatments, has entered into a securities purchase agreement with an institutional investor to facilitate a registered direct offering. Through this effort, the company will issue around 5,142,858 shares of common stock, reflecting their commitment to advancing innovative oncology therapies.
Details of the Offering
The offering, which is worth $9 million before any deductions for fees or expenses, provides Citius Oncology with the necessary capital to further its ambitious research and development efforts. This concurrent private placement will see the issuance of unregistered warrants alongside the common stock shares. The effective price for each combined share and warrant stands at $1.75, with warrants exercisable at $1.84 per share six months post-issuance.
Agent Involved
Maxim Group LLC has taken the role of the sole placement agent for this offering. Their expertise in the financial sector will help streamline the transaction and ensure it meets all regulatory requirements.
Projected Completion Timeline
The transaction is anticipated to close soon, pending the fulfillment of customary closing conditions. This is a crucial period for Citius as they aim to leverage these funds toward the development of groundbreaking treatments aimed at improving patient outcomes.
Innovations in Oncology Treatments
Citius Oncology is at the forefront of developing novel targeted therapies, with its leading product, LYMPHIR, recently receiving FDA approval for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). This significant achievement underscores the company's potential in a market estimated to exceed $400 million, highlighting an essential need yet to be adequately met by existing therapies.
IP and Competitive Positioning
The company's competitive edge is bolstered by robust intellectual property protections, including orphan drug designations and pending patents. Such protections serve as a vital foundation for ongoing and future product developments, allowing Citius to establish a strong foothold in the oncology market.
A Future Focused on Expansion
Citius Oncology aims to not only advance its current pipeline but also expand its portfolio of treatments. With financial backing through this recent offering, the potential to explore additional therapies becomes a viable next step, addressing critical therapeutic gaps in oncology.
About Citius Oncology and Citius Pharmaceuticals
Citius Oncology, Inc. operates under the umbrella of Citius Pharmaceuticals, Inc., retaining an 84% ownership stake. Citius Pharma is recognized for its commitment to first-in-class critical care products, including its FDA-approved Mino-Lok®, designed to treat patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), which provides relief for hemorrhoids.
Investor Relations
For further inquiries, interested parties can reach out to Ilanit Allen at Citius Pharmaceuticals via email at ir@citiuspharma.com or phone at 908-967-6677 x113.
Media Contact Information
Media representatives can connect with Greg Salsburg at STiR communications via email at Greg@STiR-communications.com.
Frequently Asked Questions
What is the total amount raised by Citius Oncology?
Citius Oncology raised approximately $9 million through a registered direct offering and concurrent private placement.
Who is serving as the placement agent for this offering?
Maxim Group LLC is acting as the sole placement agent for the offering.
What is LYMPHIR approved for?
LYMPHIR is FDA-approved for the treatment of adults with relapsed or refractory CTCL.
How many shares are being offered in the direct offering?
A total of 5,142,858 shares of common stock are being offered in the registered direct offering.
Who can I contact for investor inquiries about the offering?
For investor inquiries, you can reach Ilanit Allen at Citius Pharmaceuticals.
